X-linked Hypophosphatemia Clinical Trial
Official title:
An Investigator-sponsored Phase 3b Open-label Study of Anti- FGF23 Antibody Burosumab (KRN23) in Adult Patients With Xlinked Hypophosphatemia (XLH) in GERmany - BurGER
X-linked hypophosphatemia (XLH) rare genetic disorder due by inactivating mutations in the PHEX gene leading to increased levels in FGF-23. Elevated FGF-23 reduces renal phosphate reabsorbtion and and limits 1-alpha hydroxylase driven Vitamin D activation, eventually leading to phosphate wasting, defective bone mineralization and additional health issues. Burosumab is a recombinant fully human IgG1 monoclonal antibody developed to treat XLH by binding FGF23, thereby restoring normal phosphate homeostasis. BUR03 is a Phase 3b open-label, single-arm, single-center study to confirm the efficacy and safety of Burosumab treatment in adult (age ≥18 years) XLH patients without upper age limit and irrespective of baseline pain level and to further evaluate the efficacy in this cohort and the assocaited effect of treatment on physical functioning, mobility and activity. The study aims at enrolling and treating 34 subjects with a confirmed diagnosis of XLH with q4w s.c. injection of Burosumab 1mg/kg body weight over 48 weeks. Primary objective is to attiain normal serum phosphorus levels, secondary objectives include key parameters of physical function and activity, mobility and mineral homeostasis.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02915705 -
Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)
|
Phase 3 | |
| Recruiting |
NCT03879915 -
Dental Implants in Patients With X-linked Hypophosphatemia
|
||
| Active, not recruiting |
NCT03193476 -
Registry for Patients With X-Linked Hypophosphatemia
|
||
| Completed |
NCT02526160 -
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
|
Phase 3 | |
| Completed |
NCT05181839 -
A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth
|
||
| Completed |
NCT04146935 -
Examining the Effect of Burosumab on Muscle Function
|
Phase 4 | |
| Completed |
NCT02750618 -
Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
|
Phase 2 | |
| Active, not recruiting |
NCT03745521 -
Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners
|
||
| Completed |
NCT03920072 -
Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
|
Phase 3 | |
| Recruiting |
NCT03748966 -
Calcitriol Monotherapy for X-Linked Hypophosphatemia
|
Early Phase 1 | |
| Recruiting |
NCT04419363 -
Burosumab in Children and Adolescents With X-linked Hypophosphatemia
|
Phase 4 | |
| Completed |
NCT02163577 -
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
|
Phase 2 | |
| Active, not recruiting |
NCT03651505 -
X-linked Hypophosphatemia Disease Monitoring Program
|
||
| Completed |
NCT06067932 -
Foot Disorders in X-linked Hypophosphatemia
|
||
| Completed |
NCT02312687 -
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
|
Phase 2 | |
| Completed |
NCT03596554 -
X-linked Hypophosphatemia and FGF21
|
||
| Recruiting |
NCT03820518 -
Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia
|
Phase 4 | |
| Completed |
NCT01571596 -
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
|
Phase 1/Phase 2 | |
| Completed |
NCT04273490 -
Characterising Pain, QoL, Body Composition, Arterial Stiffness, Muscles and Bones in Adult Persons With XLH and Healthy Controls
|
||
| Completed |
NCT03489993 -
FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)
|